Entering text into the input field will update the search result below

ELYM Eliem Therapeutics, Inc.
Stock Price & Overview

$2.610.10 (+3.98%)4:00 PM 12/08/23
NASDAQ | $USD | Post-Market: $2.61 4:00 PM


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

People Also Follow

Company Profile

Eliem Therapeutics, Inc. logo
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.
  • 23515 NE Novelty Hill Road
  • Suite B221 #125
  • Redmond, WA, 98053
  • United States
Phone Number
877 354 3689
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.